Company’s first-in-class PDE9 inhibitor for heart failure and first-in-class CaMKII inhibitor move into later-stage clinical trials in cardiovascular diseases Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator July…
According to filings with the U.S. Securities and Exchange Commission, Cardurion Pharmaceuticals is raising $17,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Peter Lawrence played a key role in…
Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Cardurion Pharmaceuticals is raising $300,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Peter Lawrence played a…
Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Cardurion Pharmaceuticals is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Mendelsohn played a…